Zimmer Biomet appoints Embecta CEO Devdatt Kurdikar to Board of Directors

ZIMMER BIOMET HOLDINGS, INC.

Board expanded from 10 to 11 members; Devdatt Kurdikar appointed effective June 20, 2024.
Kurdikar serves as President & CEO of Embecta Corp. (Nasdaq: EMBC), a diabetes management spinoff from BD.
He will serve on the Corporate Governance Committee and Compensation & Management Development Committee.
His term expires at the 2025 annual meeting; standard non-employee director compensation applies.
No arrangements or material interests disclosed; indemnification agreement expected.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Devdatt Kurdikar

Director

ZBH · ZIMMER BIOMET HOLDINGS, INC.

Effective: 2024-06-20
Filed: June 20, 2024, 7:59 PM ET

On June 20, 2024, the Board of Directors (the “Board”) of Zimmer Biomet Holdings, Inc. (the “Company”), upon the recommendation of the Corporate Governance Committee, increased the size of the Board from ten members to eleven members and appointed Devdatt Kurdikar to fill the resulting vacancy

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Devdatt Kurdikar was appointed as Director at ZIMMER BIOMET HOLDINGS, INC..

Action: appointed
Role: Director

Exact text from the filing

On June 20, 2024, the Board of Directors (the “Board”) of Zimmer Biomet Holdings, Inc. (the “Company”), upon the recommendation of the Corporate Governance Committee, increased the size of the Board from ten members to eleven members and appointed Devdatt Kurdikar to fill the resulting vacancy

View on SEC.gov

ZIMMER BIOMET HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-075310

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.